Hello, everyone, and welcome to the middle of the week. You made it this far, so why not celebrate with a nice cup of stimulation? Remember, no prescription is required. Meanwhile, another busy day is already underway and shows no sign of slowing down. So time to get cracking. As always, we have assembled a few items of interest to help you along. Hope your day goes well and, of course, do keep in touch. We appreciate tips and insights …
Martin Shkreli may face additional charges of securities fraud concerning his involvement with Retrophin, a drug company that he ran before heading Turing Pharmaceuticals, Reuters reports. At a federal court hearing in Brooklyn, N.Y., on Tuesday, a prosecutor said the added charges could be filed within a month.
The US Food and Drug Administration warned of rare cases in which patients taking the Abilify antipsychotic pill experienced uncontrollable urges to gamble, binge eat, shop and engage in sex, STAT tells us. The drug was approved 13 years ago and, since then, only 167 reports of significant impulse-control problems were reported. In the United States, 1.6 million patients received Abilify prescriptions last year.
About the Author Reprints
